154 related articles for article (PubMed ID: 35357160)
1. Discovery of Thieno[2,3-
Lu Z; Cao Y; Zhang D; Meng X; Guo B; Kong D; Yang Y
J Med Chem; 2022 Apr; 65(7):5724-5750. PubMed ID: 35357160
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer
Xie B; Yin Z; Hu Z; Lv J; Du C; Deng X; Huang Y; Li Q; Huang J; Liang K; Zhou HB; Dong C
J Med Chem; 2023 May; 66(10):6631-6651. PubMed ID: 37161783
[TBL] [Abstract][Full Text] [Related]
3. Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.
Zhang X; Wang Y; Li X; Wu J; Zhao L; Li W; Liu J
J Med Chem; 2021 Jun; 64(11):7575-7595. PubMed ID: 34056898
[TBL] [Abstract][Full Text] [Related]
4. Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.
Govek SP; Nagasawa JY; Douglas KL; Lai AG; Kahraman M; Bonnefous C; Aparicio AM; Darimont BD; Grillot KL; Joseph JD; Kaufman JA; Lee KJ; Lu N; Moon MJ; Prudente RY; Sensintaffar J; Rix PJ; Hager JH; Smith ND
Bioorg Med Chem Lett; 2015 Nov; 25(22):5163-7. PubMed ID: 26463130
[TBL] [Abstract][Full Text] [Related]
5. Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.
Tria GS; Abrams T; Baird J; Burks HE; Firestone B; Gaither LA; Hamann LG; He G; Kirby CA; Kim S; Lombardo F; Macchi KJ; McDonnell DP; Mishina Y; Norris JD; Nunez J; Springer C; Sun Y; Thomsen NM; Wang C; Wang J; Yu B; Tiong-Yip CL; Peukert S
J Med Chem; 2018 Apr; 61(7):2837-2864. PubMed ID: 29562737
[TBL] [Abstract][Full Text] [Related]
6. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
Wang L; Sharma A
ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
[TBL] [Abstract][Full Text] [Related]
7. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
8. Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.
Govek SP; Bonnefous C; Julien JD; Nagasawa JY; Kahraman M; Lai AG; Douglas KL; Aparicio AM; Darimont BD; Grillot KL; Joseph JD; Kaufman JA; Lee KJ; Lu N; Moon MJ; Prudente RY; Sensintaffar J; Rix PJ; Hager JH; Smith ND
Bioorg Med Chem Lett; 2019 Feb; 29(3):367-372. PubMed ID: 30587451
[TBL] [Abstract][Full Text] [Related]
9. Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.
Xin L; Min J; Hu H; Li Y; Du C; Xie B; Cheng Y; Deng X; Deng X; Shen K; Huang J; Chen CC; Guo RT; Dong C; Zhou HB
Eur J Med Chem; 2023 May; 253():115328. PubMed ID: 37037140
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.
Lu Y; Gutgesell LM; Xiong R; Zhao J; Li Y; Rosales CI; Hollas M; Shen Z; Gordon-Blake J; Dye K; Wang Y; Lee S; Chen H; He D; Dubrovyskyii O; Zhao H; Huang F; Lasek AW; Tonetti DA; Thatcher GRJ
J Med Chem; 2019 Dec; 62(24):11301-11323. PubMed ID: 31746603
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα
Puyang X; Furman C; Zheng GZ; Wu ZJ; Banka D; Aithal K; Agoulnik S; Bolduc DM; Buonamici S; Caleb B; Das S; Eckley S; Fekkes P; Hao MH; Hart A; Houtman R; Irwin S; Joshi JJ; Karr C; Kim A; Kumar N; Kumar P; Kuznetsov G; Lai WG; Larsen N; Mackenzie C; Martin LA; Melchers D; Moriarty A; Nguyen TV; Norris J; O'Shea M; Pancholi S; Prajapati S; Rajagopalan S; Reynolds DJ; Rimkunas V; Rioux N; Ribas R; Siu A; Sivakumar S; Subramanian V; Thomas M; Vaillancourt FH; Wang J; Wardell S; Wick MJ; Yao S; Yu L; Warmuth M; Smith PG; Zhu P; Korpal M
Cancer Discov; 2018 Sep; 8(9):1176-1193. PubMed ID: 29991605
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
[TBL] [Abstract][Full Text] [Related]
13. A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER+ breast cancer.
Wang B; Ma M; Dai Y; Yu P; Ye L; Wang W; Sha C; Yang H; Yang Y; Zhu Y; Dong L; Wei S; Wang L; Tian J; Wang H
Eur J Med Chem; 2024 Jan; 264():115934. PubMed ID: 38007911
[TBL] [Abstract][Full Text] [Related]
14. Dual-target inhibitors based on ERα: Novel therapeutic approaches for endocrine resistant breast cancer.
Xiong S; Song K; Xiang H; Luo G
Eur J Med Chem; 2024 Apr; 270():116393. PubMed ID: 38588626
[TBL] [Abstract][Full Text] [Related]
15. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
[TBL] [Abstract][Full Text] [Related]
16. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
[TBL] [Abstract][Full Text] [Related]
17. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
[TBL] [Abstract][Full Text] [Related]
18. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.
Lu Y; Liu C; Wang X; Liu L; Zhao Z; Liang Z; Liu Y; Wen Z; Du Q; Liu W
Eur J Med Chem; 2023 May; 253():115324. PubMed ID: 37019030
[TBL] [Abstract][Full Text] [Related]
20. Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer.
Chen YC; Yu J; Metcalfe C; De Bruyn T; Gelzleichter T; Malhi V; Perez-Moreno PD; Wang X
Expert Opin Investig Drugs; 2022 Jun; 31(6):515-529. PubMed ID: 34694932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]